Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitam ...
AGOURA HILLS, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("OTLC" or the "Company"), a clinical-stage ...
AbbVie ABBV has been consistently increasing its R&D investments to support long-term growth across multiple therapeutic areas. The company’s pipeline spans immunology therapies, expanding oncology ...
Earnings Call Insights: Harmony Biosciences Holdings, Inc. (HRMY) Q2 2025 Management reiterated full year revenue guidance of $820 million to $860 million and maintained their projection that WAKIX is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results